Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (cDMARDs) in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors

RMD Open - United Kingdom
doi 10.1136/rmdopen-2018-000692
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Efficacy and Safety of Baricitinib for Active Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic or Biological Disease‑modifying Anti‑rheumatic Drugs: A Meta‑analysis of Randomized Controlled Trials

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond

RMD Open
RheumatologyAllergyImmunology
2019English

Comparison of the Efficacy of the Tumour Necrosis Factor Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients With Active Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Assessing the Effectiveness of Synthetic and Biologic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis &Ndash; A Systematic Review

Psoriasis: Targets and Therapy
DermatologyRheumatology
2015English

Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs

Reumatologia
RheumatologyAllergyImmunology
2014English

Comparative Effectiveness of Tocilizumab Versus TNF Inhibitors as Monotherapy or in Combination With Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis After the Use of at Least One Biologic Disease-Modifying Antirheumatic Drug: Analyses From the Pan-European TOCERRA Register Collaboration

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Cost-Effectiveness of Combination Disease-Modifying Antirheumatics vs. Tumour Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: TACIT Trial

Arthritis Care and Research
Rheumatology
2020English

Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study

Arthritis Research & Therapy
2019English

Association Between Use of Disease-Modifying Antirheumatic Drugs and Diabetes in Patients With Ankylosing Spondylitis, Rheumatoid Arthritis, or Psoriasis/Psoriatic Arthritis: A Nationwide, Population-Based Cohort Study of 84,989 Patients

Therapeutics and Clinical Risk Management
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy